IP Library › Granted Patent US 12,304,968
Granted Patent B2
US 12,304,968 · App. 16/677,267 · Granted May 20, 2025

T-cells expressing anti-LIV1 chimeric antigen receptor

Inventors: Jonathan Alexander Terrett (Cambridge, MA); Jason Sagert (Cambridge, MA)
Assignee: CRISPR THERAPEUTICS AG
C07K16/3015A61K39/3955A61K40/11A61K40/31A61K40/32A61K40/4202A61K40/421A61P35/00C07K14/4717C07K14/705C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K16/28C07K19/00C12N5/0636C12N9/22C12N15/11C12N15/85C12N15/86A61K38/00A61K2239/49A61K2239/56C07K2317/565C07K2317/622C07K2317/73C07K2317/76C07K2319/02C07K2319/03C07K2319/30C07K2319/33C12N2310/20C12N2502/30C12N2502/99C12N2510/00C12N2750/14143C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,968
App. No.
16/677,267
Granted
May 20, 2025
Kind
B2
Abstract

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1 + malignancies.

Claims (12)

1. An engineered T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR) encoded by the nucleotide sequence of any one of SEQ ID NOs: 49, 51, 104, and 108.

2. The engineered T cell of claim 1 further comprising a disrupted T cell receptor alpha chain constant region (TRAC) gene.

3. The engineered T cell of claim 2 , wherein the nucleic acid encoding the CAR is inserted into the disrupted TRAC gene.

4. The engineered T cell of claim 2 , wherein the disrupted TRAC gene comprises the nucleotide sequence of any one of SEQ ID NOs: 63, 64, 107, and 111.

5. The engineered T cell of claim 2 , wherein the disrupted TRAC gene comprises the nucleotide sequence of SEQ ID NO: 107.

6. The engineered T cell of claim 1 further comprising a disrupted beta-2-microglobulin (β2M) gene.

7. The engineered T cell of claim 1 , wherein the CAR further comprises a CD28 co-stimulatory domain or a 41BB co-stimulatory domain.

8. The engineered T cell of claim 7 , wherein the CAR further comprises a CD3 cytoplasmic signaling domain.

9. The engineered T cell of claim 1 , wherein the T cell is a human T cell.

10. A population of cells comprising the engineered T cell of claim 1 , wherein at least 15% or at least 50% of the engineered T cells of the population express the CAR.

11. The engineered T cell of claim 1 , wherein the CAR comprises an anti-LIV1 scFv having the amino acid sequence of SEQ ID NO: 83.

12. The engineered T cell of claim 1 , wherein the CAR comprises the amino acid sequence of SEQ ID NO: 105.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2021
From: TERRETT, JONATHAN ALEXANDER; SAGERT, JASON
To: CRISPR THERAPEUTICS AG
Reel/Frame 055945/0579 →
Continuity (2)
Provisional Application 62756723 · Nov 7, 2018
Related Publication 20200231699A1 · Jul 23, 2020
References Cited (55)
US 5858358A · June et al. · 1999 [cited by applicant]
US 5883223A · Gray · 1999 [cited by applicant]
US 6140081A · Barbas · 2000 [cited by applicant]
US 6352694B1 · June et al. · 2002 [cited by applicant]
US 6453242B1 · Eisenberg et al. · 2002 [cited by applicant]
US 6534055B1 · June et al. · 2003 [cited by applicant]
US 6534261B1 · Cox et al. · 2003 [cited by applicant]
US 6692964B1 · June et al. · 2004 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6887466B2 · June et al. · 2005 [cited by applicant]
US 6905680B2 · June et al. · 2005 [cited by applicant]
US 6905681B1 · June et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7067318B2 · June et al. · 2006 [cited by applicant]
US 7144575B2 · June et al. · 2006 [cited by applicant]
US 7172869B2 · June et al. · 2007 [cited by applicant]
US 7175843B2 · June et al. · 2007 [cited by applicant]
US 7232566B2 · June et al. · 2007 [cited by applicant]
US 7888121B2 · Urnov et al. · 2011 [cited by applicant]
US 7972854B2 · Miller et al. · 2011 [cited by applicant]
US 9228026B2 · Smith et al. · 2016 [cited by applicant]
US 20110145940A1 · Voytas et al. · 2011 [cited by applicant]
CA 3041039A1 · 2018 [cited by applicant]
EP 3156420A1 · 2017 [cited by applicant]
WO 9853058A1 · 1998 [cited by applicant]
WO 9853059A1 · 1998 [cited by applicant]
WO 9853060A1 · 1998 [cited by applicant]
WO 0216536A1 · 2002 [cited by applicant]
WO 0316496A2 · 2003 [cited by applicant]
WO 2016069282A1 · 2016 [cited by applicant]
WO 2017161007 · 2017 [cited by applicant]
WO 2018027036A1 · 2018 [cited by applicant]
WO 2018073393 · 2018 [cited by applicant]
WO WO2018102795A2 · 2018 [cited by examiner]
Kim et al, 2021. Frontiers in Immunology 12: 1-12. [cited by examiner]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Ferrara et al (2015. mAbs. 7(1): 32-41). [cited by examiner]
Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins, J. Mol. Biol., 273:927-948 (1997). [cited by applicant]
Almagro, Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires, J. Mol. Recognit., 17… [cited by applicant]
Bauer et al., Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9, Vis. Exp., 95:e52118 (2015). [cited by applicant]
Chang et al., Modification of DNA ends can decrease end joining relative to homologous recombination in mammalian cells, Proc. Natl. Acad. Sci. USA., 84:4959-4963 (1987). [cited by applicant]
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., 196:901-917 (1987). [cited by applicant]
Chothia et al., Conformations of immunoglobulin hypervariable regions, Nature, 342:877-883 (1989). [cited by applicant]
Deltcheva et al., CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III, Nature, 471:602-607 (2011). [cited by applicant]
Enblad et al., CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma, Hum. Gen. Ther., 26:498-505 (2015). [cited by applicant]
Eyquem et al., Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature, 543:113-117 (2017). [cited by applicant]
International Application No. PCT/IB2019/059586, International Search Report and Written Opinion, mailed Feb. 7, 2020. [cited by applicant]
Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, 337:816-821 (2012). [cited by applicant]
Kakarla et al., CAR T cells for solid tumors: armed and ready to go?, Cancer J., 20:151-155 (2014). [cited by applicant]
Liu et al., CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells, Cell Res., 27(1):154-157 (2017). [cited by applicant]
Maude et al., CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood, 125:4017-4023 (2015). [cited by applicant]
Nehls et al., Two genetically separable steps in the differentiation of thymic epithelium, Science, 272:886-889 (1996). [cited by applicant]
Ren et al., A versatile system for rapid multiplex genome-edited CAR T cell generation, Oncot., 8(10):17002-17011 (2017). [cited by applicant]
Ren et al., Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition, Clin. Cancer Res., 23(9):2255-2266 (2016). [cited by applicant]